Summary
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 50 | $1,250 | $599.55 | -$650.45 | -52.04% |
| CE Curtis Ellergodt Rothschild Investment LLC | 227 | $1,162.56 | $2,721.98 | $1,559.42 | 134.14% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 10 | $149.1 | $118.04 | -$31.06 | -20.83% |
| BG Bart Gancher Intech Investment Management LLC | 26,266 | $364,494.3 | $310,211.97 | -$54,282.33 | -14.89% |
 Point72 Asset Management LP Point72 Asset Management LP | 71,107 | $1.65M | $832,662.97 | -$813,673.57 | -49.42% |
Olema Pharmaceuticals Inc. (OLMA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Olema Pharmaceuticals Inc. ever had a stock split?
Olema Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sean Bohen CEO | NASDAQ (NGS) Exchange | 68062P106 CUSIP |
| US Country | 137 Employees | - Last Dividend | - Last Split | 19 Nov 2020 IPO Date |
Overview
Olema Pharmaceuticals, Inc. is a forward-thinking clinical-stage biopharmaceutical company that has dedicated its research and development efforts toward creating innovative therapies specifically designed for women’s cancers. Established initially as CombiThera, Inc., the company underwent a name change to Olema Pharmaceuticals, Inc. in March 2009, signaling a renewed focus and commitment to its mission. Olema Pharmaceuticals is based in San Francisco, California, and has been advancing cancer treatment options since its inception in 2006. The company’s strategic approach to combating women’s cancers through groundbreaking therapies showcases its commitment to addressing the needs of patients battling these diseases.
Products and Services
- OP-1250
- Combination Therapy with CDK4/6 Inhibitors
- OPERA-01
OP-1250 represents the forefront of Olema Pharmaceuticals’ innovative product lineup, functioning as both an estrogen receptor (ER) antagonist and a selective ER degrader. This cutting-edge compound is currently undergoing a Phase 3 clinical trial aimed at treating recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The development of OP-1250 is significant due to its potential to offer a more effective treatment option for patients with this type of breast cancer, addressing a major unmet medical need.
Expanding on the potential of OP-1250, Olema Pharmaceuticals is exploring its combination with CDK4/6 inhibitors such as palbociclib, ribociclib, and alpelisib. This innovative approach is currently in Phase 1/2 clinical trials, focusing on the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. By leveraging the synergy between OP-1250 and CDK4/6 inhibitors, the company aims to enhance the efficacy of treatment and provide new hope to patients affected by this challenging condition.
With OPERA-01, Olema Pharmaceuticals further extends its commitment to addressing women’s cancers, targeting ER+/HER2- advanced or metastatic breast cancer. This developmental project signifies the company’s ongoing efforts to broaden its portfolio and bring forth new, effective treatments in the fight against breast cancer, emphasizing a patient-centric approach in oncology.
